Turoctocog alfa
- Generic Name
- Turoctocog alfa
- Brand Names
- Novoeight, Zonovate, NovoEight
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1192451-26-5
- Unique Ingredient Identifier
- 969NZA3X9T
- Background
Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. During sec...
- Indication
Turoctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A. The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management. Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This di...
- Associated Conditions
- Bleeding
- Associated Therapies
- -
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 900
- Registration Number
- NCT06574984
Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT04584892
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Vicenza, Italy
Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1
- Registration Number
- NCT03588741
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT03449342
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, New Delhi, India
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT03196297
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT03179748
- Locations
- 🇲🇽
Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
- Conditions
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 35
- Registration Number
- NCT02941354
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
- Conditions
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 68
- Registration Number
- NCT02938585
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Hangzhou, Zhejiang, China
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT02207218
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 69
- Registration Number
- NCT02035384
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.